BOEHRINGER, LILLY START TRAJENTA MARLINAT CLINICAL TRIAL (ENG)

     (The following press release from Boehringer Ingelheim was received by 
e-mail. It was not confirmed by the sender.) 
Dear Sir/Madam, 
Enclosed you will find our latest press release 
For Non-U.S. and Non-U.K. Media 
Boehringer Ingelheim and Lilly initiate MARLINA(tm) clinical trial to
evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and
albuminuria 
which can be accessed at: 
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/19_ma
rch_2013_linagliptin.html 
All interested users with a web-enabled mobile phone, iPhone, Blackberry, PDA
or other mobile device now have fast access to selected, up-to-the-minute
information about Boehringer Ingelheim.
Just follow: http://mobile.boehringer-ingelheim.com/ 
Mit freundlichen Grüßen / Kind regards, 
Arnd Prilipp 
Boehringer Ingelheim GmbH
Launch + establ. Products CVM
Tel.: +49 (6132) 77-2091
Fax: +49 (6132) 77-6601
mailto:press@boehringer-ingelheim.com 
Visit us...
 <http://www.boehringer-ingelheim.com/>  <<Picture (Device Independent
Bitmap)>>  <http://www.facebook.com/boehringeringelheim>  <<Picture (Device
Independent Bitmap)>>  <http://www.twitter.com/boehringer>  <<Picture (Device
Independent Bitmap)>>  <http://www.youtube.com/boehringeringelheim>  
<<Picture (Device Independent Bitmap)>>
<http://www.flickr.com/photos/125yearsmorehealth/>  <<Picture (Device
Independent Bitmap)>> 
Boehringer Ingelheim GmbH, Unternehmensleitung: Prof. Dr. Dr. Andreas Barner
(Sprecher), Hubertus von Baumbach, Prof. Dr. Wolfram Carius, Engelbert Tjeenk
Willink; Vorsitzender des Aufsichtsrates: Christian Boehringer, Sitz:
Ingelheim am Rhein; Registergericht Mainz: HR B 21005  
Diese E-Mail ist vertraulich zu behandeln. Sie kann besonderem rechtlichen
Schutz unterliegen. Wenn Sie nicht der richtige Adressat sind, senden Sie
bitte diese E-Mail an den Absender zurück, löschen die eingegangene E-Mail
und geben den Inhalt der E-Mail nicht weiter. Jegliche unbefugte Bearbeitung,
Nutzung, Vervielfältigung oder Verbreitung ist verboten. / This e-mail is
confidential and may also be legally privileged. If you are not the intended
recipient please reply to sender, delete the e-mail and do not disclose its
contents to any person. Any unauthorized review, use, disclosure, copying or
distribution is strictly prohibited.